Perspectives

Pharmacist intervention may help identify potential opioid abuse early

Concurrent drug utilization review catches opioid abuse upstream

July 21, 2016

Concurrent drug utilization review (DUR) may cast wider net for catching potential opioid abuse upstream

A pharmacist intervention (DUR) may impact potential opioid misuse and abuse. This study identified at-risk members at the time they submit their opioid prescription. A soft edit (point of service) intervention delayed or altered claims for 42% of the members in the study.

Impact of a Concurrent Drug Utilization Review Edit Designed to Curb Opioid Misuse (Spring 2016)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit www.primetherapeutics.com and www.magellanrx.com, or follow us on Twitter at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

September 25, 2023

Specialty Drug Pipeline Quarterly Update: September 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

Read More

Perspectives

September 25, 2023

Traditional Drug Pipeline Quarterly Update: September 2023

This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…

Read More

Perspectives

September 25, 2023

Gene/Cell Therapy Quarterly Update: September 2023

This quarterly pipeline wrap-up provides a review of newly approved gene and cell…

Read More
View all news